ArticleThe Journal of clinical investigation1999
Cell-wall determinants of the bactericidal action of group IIA phospholipase A2 against Gram-positive bacteria.
Article in The Journal of clinical investigation, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 104 citations in OpenAlex.
- Antibacterial Activities of Recombinant Phospholipase rSlaAYE1 from Streptococcus pyogenes ADUYE1.Probiotics and antimicrobial proteins · 2026Article
- Bacteroides uniformis CECT 7771 requires adaptive immunity to improve glucose tolerance but not to prevent body weight gain in diet-induced obese mice.Microbiome · 2024Article
- The interaction of secreted phospholipase A2-IIA with the microbiota alters its lipidome and promotes inflammation.JCI insight · 2022Article
- Bacteriophage Lytic Enzyme P9ly as an Alternative Antibacterial Agent Against Antibiotic-ResistantFrontiers in microbiology · 2022Article
- Modulation of the immune response by theFrontiers in cellular and infection microbiology · 2022Review
- Human Group IIA Phospholipase AMolecules (Basel, Switzerland) · 2021Review
- Streptococcal Lancefield polysaccharides are critical cell wall determinants for human Group IIA secreted phospholipase A2 to exert its bactericidal effects.PLoS pathogens · 2018Article
- Group IIA-Secreted Phospholipase AInfection and immunity · 2018Article
- Turgor Pressure and Possible Constriction Mechanisms in Bacterial Division.Frontiers in microbiology · 2018Review
- How bacterial cell division might cheat turgor pressure - a unified mechanism of septal division in Gram-positive and Gram-negative bacteria.BioEssays : news and reviews in molecular, cellular and developmental biology · 2017Review
- Molecular determinants of bacterial sensitivity and resistance to mammalian Group IIA phospholipase A2.Biochimica et biophysica acta · 2015Review
- Lipidome and transcriptome profiling of pneumolysin intoxication identifies networks involved in statin-conferred protection of airway epithelial cells.Scientific reports · 2015Article
- Intestinal dysbiosis and bacterial enteroinvasion in a murine model of Hirschsprung's disease.Journal of pediatric surgery · 2014Article
- IL-25 improves luminal innate immunity and barrier function during parenteral nutrition.Annals of surgery · 2014Article
- Route and type of nutrition and surgical stress influence secretory phospholipase A2 secretion of the murine small intestine.JPEN. Journal of parenteral and enteral nutrition · 2011Article
- Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention.Chemical reviews · 2011Review
- Role of net charge on catalytic domain and influence of cell wall binding domain on bactericidal activity, specificity, and host range of phage lysins.The Journal of biological chemistry · 2011Article
- Genetics of kidney failure and the evolving story of APOL1.The Journal of clinical investigation · 2011Review
- Characterization of Staphylococcus aureus cardiolipin synthases 1 and 2 and their contribution to accumulation of cardiolipin in stationary phase and within phagocytes.Journal of bacteriology · 2011Article
- Bacterial resistance mechanisms against host defense peptides.Cellular and molecular life sciences : CMLS · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
We have shown previously that a group IIA phospholipase A2 (PLA2) is responsible for the potent bactericidal activity of inflammatory fluids against many Gram-positive bacteria. To exert its antibacterial activity, this PLA2 must first bind and traverse the bacterial cell wall to produce the extensive degradation of membrane phospholipids (PL) required for bacterial killing. In this study, we have examined the properties of the cell-wall that may determine the potency of group IIA PLA2 action. Inhibition of bacterial growth by nutrient deprivation or a bacteriostatic antibiotic reversibly increased bacterial resistance to PLA2-triggered PL degradation and killing. Conversely, pretreatment of Staphylococcus aureus or Enterococcus faecium with subinhibitory doses of beta-lactam antibiotics increased the rate and extent of PL degradation and/or bacterial killing after addition of PLA2. Isogenic wild-type (lyt+) and autolysis-deficient (lyt-) strains of S. aureus were equally sensitive to the phospholipolytic action of PLA2, but killing and lysis was much greater in the lyt+ strain. Thus, changes in cell-wall cross-linking and/or autolytic activity can modulate PLA2 action either by affecting enzyme access to membrane PL or by the coupling of massive PL degradation to autolysin-dependent killing and bacterial lysis or both. Taken together, these findings suggest that the bacterial envelope sites engaged in cell growth may represent preferential sites for the action and cytotoxic consequences of group IIA PLA2 attack against Gram-positive bacteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.